AAAAAA

   
Results: 1-10 |
Results: 10
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer
Authors: Lippman, SM Lee, JJ Karp, DD Vokes, EE Benner, SE Goodman, GE Khuri, FR Marks, R Winn, RJ Fry, W Graziano, SL Gandara, DR Okawara, G Woodhouse, CL Williams, B Perez, C Kim, HW Lotan, R Roth, JA Hong, WK
Citation: Sm. Lippman et al., Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer, J NAT CANC, 93(8), 2001, pp. 605-618
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial
Authors: Khuri, FR Kim, ES Lee, JJ Winn, RJ Benner, SE Lippman, SM Fu, KK Cooper, JS Vokes, EE Chamberlain, RM Williams, B Pajak, TF Goepfert, H Hong, WK
Citation: Fr. Khuri et al., The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial, CANC EPID B, 10(8), 2001, pp. 823-829
The NCCN guidelines development process and infrastructure
Authors: Winn, RJ
Citation: Rj. Winn, The NCCN guidelines development process and infrastructure, ONCOLOGY-NY, 14(11A), 2000, pp. 26-30
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
Authors: Ozer, H Armitage, JO Bennett, CL Crawford, J Demetri, GD Pizzo, PA Schiffer, CA Smith, TJ Somlo, G Wade, JC Wade, JL Winn, RJ Wozniak, AJ Somerfield, MR
Citation: H. Ozer et al., 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines, J CL ONCOL, 18(20), 2000, pp. 3558-3585
Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma
Authors: Hoff, PM Ellerton, JA Dakhil, SR Winn, RJ Abbruzzese, JL Pazdur, R
Citation: Pm. Hoff et al., Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma, AM J CL ONC, 23(6), 2000, pp. 602-604
Reproducibility of guidelines - A comparison of the NCCN and ASCO lung cancer guidelines
Authors: Winn, RJ Brown, NH Botnick, WZ
Citation: Rj. Winn et al., Reproducibility of guidelines - A comparison of the NCCN and ASCO lung cancer guidelines, ONCOLOGY-NY, 13(5A), 1999, pp. 35-39
The NCCN guidelines development process
Authors: Winn, RJ Brown, NH
Citation: Rj. Winn et Nh. Brown, The NCCN guidelines development process, ONCOLOGY-NY, 13(11A), 1999, pp. 28-32
Clinical practice guidelines in the management of gynecologic malignancies
Authors: Winn, RJ Teng, NNH
Citation: Rj. Winn et Nnh. Teng, Clinical practice guidelines in the management of gynecologic malignancies, HEMAT ONCOL, 13(1), 1999, pp. 63
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue - An uncontrolled trial
Authors: Steinbach, G Ford, R Glober, G Sample, D Hagemeister, FB Lynch, PM McLaughlin, PW Rodriguez, MA Romaguera, JE Sarris, AH Younes, A Luthra, R Manning, JT Johnson, CM Lahoti, S Shen, Y Lee, JE Winn, RJ Genta, RM Graham, DY Cabanillas, FF
Citation: G. Steinbach et al., Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue - An uncontrolled trial, ANN INT MED, 131(2), 1999, pp. 88
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma
Authors: Pazdur, R Medgyesy, DC Winn, RJ Dakhil, SR Moore, DF Scalzo, A Hoff, PM Arbuck, SG Abbruzzese, JL
Citation: R. Pazdur et al., Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma, INV NEW DR, 16(4), 1998, pp. 341-346
Risultati: 1-10 |